BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Jiang Y, Wei D, Singh P, Yu Y, Lee T, Zhang L, Mandl HK, Piotrowski-Daspit AS, Chen X, Li F, Li X, Cheng Y, Josowitz A, Yang F, Zhao Y, Wang F, Zhao Z, Huttner A, Bindra RS, Xiao H, Mark Saltzman W. Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance. Nat Biomed Eng 2021. [PMID: 34045730 DOI: 10.1038/s41551-021-00728-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Xu H, Zhang Y, Li L, Ren Y, Qian F, Wang L, Ma H, Quan A, Liu H, Yu R. The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma. Drug Deliv 2023;30:1-13. [PMID: 36579448 DOI: 10.1080/10717544.2022.2152911] [Reference Citation Analysis]
2 Zhang X, Hou H, Wan J, Yang J, Tang D, Zhao D, Liu T, Shang K. Inhibiting COX-2/PGE2 pathway with biodegradable NIR-Ⅱ fluorescent polymeric nanoparticles for enhanced photodynamic immunotherapy. Nano Today 2023;48:101759. [DOI: 10.1016/j.nantod.2023.101759] [Reference Citation Analysis]
3 Shi J, Zhang P, Dong X, Yuan J, Li Y, Li S, Cheng S, Ping Y, Dai X, Dong J. METTL3 knockdown promotes temozolomide sensitivity of glioma stem cells via decreasing MGMT and APNG mRNA stability. Cell Death Discov 2023;9:22. [PMID: 36683086 DOI: 10.1038/s41420-023-01327-y] [Reference Citation Analysis]
4 Wu H, Zhang T, Liu Q, Wei M, Li Y, Ma Q, Wang L, Zhu Y, Zhang H. Polydopamine-based loaded temozolomide nanoparticles conjugated by peptide-1 for glioblastoma chemotherapy and photothermal therapy. Front Pharmacol 2023;14. [DOI: 10.3389/fphar.2023.1081612] [Reference Citation Analysis]
5 Shang K, Zhang L, Yu Y, Xiao H, Gao Y, Yang L, Huang J, Song H, Han H. Disulfide-containing polymer delivery of C527 and a Platinum(IV) prodrug selectively inhibited protein ubiquitination and tumor growth on cisplatin resistant and patient-derived liver cancer models. Mater Today Bio 2023;18:100548. [PMID: 36713799 DOI: 10.1016/j.mtbio.2023.100548] [Reference Citation Analysis]
6 Cai X, Shi S, Chen G, Zhong M, Yang Y, Mai Z, Tian Y, Tan J, He L, Cui C, Yu Z, Wang X. Glutamine metabolism targeting liposomes for synergistic chemosensitization and starvation therapy in ovarian cancer. Acta Biomater 2022:S1742-7061(22)00865-0. [PMID: 36596434 DOI: 10.1016/j.actbio.2022.12.052] [Reference Citation Analysis]
7 Rong R, Zhou X, Liang G, Li H, You M, Liang Z, Zeng Z, Xiao H, Ji D, Xia X. Targeting Cell Membranes, Depleting ROS by Dithiane and Thioketal-Containing Polymers with Pendant Cholesterols Delivering Necrostatin-1 for Glaucoma Treatment. ACS Nano 2022;16:21225-39. [PMID: 36487191 DOI: 10.1021/acsnano.2c09202] [Reference Citation Analysis]
8 Wan J, Zhang X, Li Z, Mo F, Tang D, Xiao H, Wang J, Rong G, Liu T. Oxidative Stress Amplifiers as Immunogenic Cell Death Nanoinducers Disrupting Mitochondrial Redox Homeostasis for Cancer Immunotherapy. Adv Healthc Mater 2022;:e2202710. [PMID: 36527737 DOI: 10.1002/adhm.202202710] [Reference Citation Analysis]
9 Zhang L, Wang Y, Karges J, Tang D, Zhang H, Zou K, Song J, Xiao H. Tetrahedral DNA Nanostructure with Interferon Stimulatory DNA Delivers Highly Potent Toxins and Activates the cGAS-STING Pathway for Robust Chemotherapy and Immunotherapy. Adv Mater 2022;:e2210267. [PMID: 36484099 DOI: 10.1002/adma.202210267] [Reference Citation Analysis]
10 Li C, Deng Z, Gillies ER. Designing polymers with stimuli-responsive degradation for biomedical applications. Current Opinion in Biomedical Engineering 2022. [DOI: 10.1016/j.cobme.2022.100437] [Reference Citation Analysis]
11 Kang X, Bu F, Feng W, Liu F, Yang X, Li H, Yu Y, Li G, Xiao H, Wang X. Dual-Cascade Responsive Nanoparticles Enhance Pancreatic Cancer Therapy by Eliminating Tumor-Resident Intracellular Bacteria. Adv Mater 2022;34:e2206765. [PMID: 36082582 DOI: 10.1002/adma.202206765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Zhang L, Zhu L, Tang L, Xie J, Gao Y, Yu C, Shang K, Han H, Liu C, Lu Y. Glutathione-Responsive Nanoparticles of Camptothecin Prodrug for Cancer Therapy. Adv Sci (Weinh) 2023;10:e2205246. [PMID: 36442854 DOI: 10.1002/advs.202205246] [Reference Citation Analysis]
13 Lim C, Koo J, Oh KT. Nanomedicine approaches for medulloblastoma therapy. J Pharm Investig 2022. [DOI: 10.1007/s40005-022-00597-5] [Reference Citation Analysis]
14 Yu Y, Zhang L, Qin Z, Karges J, Xiao H, Su X. Unraveling and Overcoming Platinum Drug‐Resistant Cancer Tumors with DNA Nanostructures. Adv Funct Materials 2022. [DOI: 10.1002/adfm.202208797] [Reference Citation Analysis]
15 Li R, Chen Z, Li J, Dai Z, Yu Y. Nano-drug delivery systems for T cell-based immunotherapy. Nano Today 2022;46:101621. [DOI: 10.1016/j.nantod.2022.101621] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Torres ID, Loureiro JA, Coelho MAN, Carmo Pereira M, Ramalho MJ. Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance. Expert Opinion on Drug Delivery. [DOI: 10.1080/17425247.2022.2124967] [Reference Citation Analysis]
17 Huang C, Zhou Y, Tong Q, Duan Q, Zhang Q, Du J, Yao X. Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121827] [Reference Citation Analysis]
18 Zhang L, Shang K, Li X, Shen M, Lu S, Tang D, Han H, Yu Y. Reduction Sensitive Polymers Delivering Cationic Platinum Drugs as STING Agonists for Enhanced Chemo‐Immunotherapy. Adv Funct Materials. [DOI: 10.1002/adfm.202204589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Xiong G, Huang D, Lu L, Luo X, Wang Y, Liu S, Chen M, Yu S, Kappen M, You C, Lu S, Yu Y, Lu J, Lin F. Near-Infrared-II Light Induced Mild Hyperthermia Activate Cisplatin-Artemisinin Nanoparticle for Enhanced Chemo/Chemodynamic Therapy and Immunotherapy. Small Methods 2022;:e2200379. [PMID: 35978419 DOI: 10.1002/smtd.202200379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ashrafizadeh M, Aghamiri S, Tan SC, Zarrabi A, Sharifi E, Rabiee N, Kadumudi FB, Pirouz AD, Delfi M, Byrappa K, Thakur VK, Sharath Kumar KS, Girish YR, Zandsalimi F, Zare EN, Orive G, Tay F, Hushmandi K, Kumar AP, Karaman C, Karimi-maleh H, Mostafavi E, Makvandi P, Wang Y. Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology. Nano Today 2022;45:101532. [DOI: 10.1016/j.nantod.2022.101532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Bonan NF, Ledezma DK, Tovar MA, Balakrishnan PB, Fernandes R. Anti-Fn14-Conjugated Prussian Blue Nanoparticles as a Targeted Photothermal Therapy Agent for Glioblastoma. Nanomaterials 2022;12:2645. [DOI: 10.3390/nano12152645] [Reference Citation Analysis]
22 Wang Y, Wang B, Li K, Wang M, Xiao H. Engineered metal and their complexes for nanomedicine-elicited cancer immunotherapy. Materials Today Advances 2022;15:100276. [DOI: 10.1016/j.mtadv.2022.100276] [Reference Citation Analysis]
23 Ding F, Li F, Tang D, Wang B, Liu J, Mao X, Yin J, Xiao H, Wang J, Liu Z. Restoration of the Immunogenicity of Tumor Cells for Enhanced Cancer Therapy via Nanoparticle‐Mediated Copper Chaperone Inhibition. Angew Chem Int Ed 2022;61. [DOI: 10.1002/anie.202203546] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Cha GD, Jung S, Choi SH, Kim DH. Local Drug Delivery Strategies for Glioblastoma Treatment. Brain Tumor Res Treat 2022;10:151-7. [PMID: 35929112 DOI: 10.14791/btrt.2022.0017] [Reference Citation Analysis]
25 Zhang X, Wan J, Mo F, Tang D, Xiao H, Li Z, Jia J, Liu T. Targeting Bone Tumor and Subcellular Endoplasmic Reticulum via Near Infrared II Fluorescent Polymer for Photodynamic-Immunotherapy to Break the Step-Reduction Delivery Dilemma. Adv Sci (Weinh) 2022;:e2201819. [PMID: 35754296 DOI: 10.1002/advs.202201819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Le Z, He Z, Liu H, Ke J, Liu L, Liu Z, Chen Y. Orally administrable polyphenol-based nanoparticles achieve anti-inflammation and antitumor treatment of colon diseases. Biomater Sci 2022. [PMID: 35726761 DOI: 10.1039/d2bm00540a] [Reference Citation Analysis]
27 Ding F, Li F, Tang D, Wang B, Liu J, Mao X, Yin J, Xiao H, Wang J, Liu Z. Restoration of the Immunogenicity of Tumor Cells for Enhanced Cancer Therapy via Nanoparticle‐Mediated Copper Chaperone Inhibition. Angewandte Chemie. [DOI: 10.1002/ange.202203546] [Reference Citation Analysis]
28 Li X, Zhang L, Li T, Li S, Wu W, Zhao L, Xie P, Yang J, Li P, Zhang Y, Xiao H, Yu Y, Zhao Z. Abplatin(IV) inhibited tumor growth on a patient derived cancer model of hepatocellular carcinoma and its comparative multi-omics study with cisplatin. J Nanobiotechnology 2022;20:258. [PMID: 35659243 DOI: 10.1186/s12951-022-01465-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Zha S, Wong KL, All AH. Intranasal Delivery of Functionalized Polymeric Nanomaterials to the Brain. Adv Healthc Mater 2022;11:e2102610. [PMID: 35166052 DOI: 10.1002/adhm.202102610] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
30 Zheng J, Sun Y, Long T, Yuan D, Yue S, Zhang N, Yang Z. Sonosensitizer nanoplatform-mediated sonodynamic therapy induced immunogenic cell death and tumor immune microenvironment variation. Drug Deliv 2022;29:1164-75. [PMID: 35393920 DOI: 10.1080/10717544.2022.2058653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Peña Q, Wang A, Zaremba O, Shi Y, Scheeren HW, Metselaar JM, Kiessling F, Pallares RM, Wuttke S, Lammers T. Metallodrugs in cancer nanomedicine. Chem Soc Rev 2022. [PMID: 35262108 DOI: 10.1039/d1cs00468a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
32 Shan X, Gong X, Li J, Wen J, Li Y, Zhang Z. Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.02.025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
33 Tian L, Shao M, Gong Y, Wei T, Zhu Y, Chao Y, Liu Z. Epigenetic Platinum Complexes Breaking the "Eat Me/Don't Eat Me" Balance for Enhanced Cancer Chemoimmunotherapy. Bioconjug Chem 2022. [PMID: 35040313 DOI: 10.1021/acs.bioconjchem.1c00576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Xie P, Jin Q, Li Y, Zhang J, Kang X, Zhu J, Mao X, Cao P, Liu C. Nanoparticle delivery of a triple-action Pt(IV) prodrug to overcome cisplatin resistance via synergistic effect. Biomater Sci 2021;10:153-7. [PMID: 34811566 DOI: 10.1039/d1bm01556g] [Reference Citation Analysis]
35 Zhang R, Nie T, Fang Y, Huang H, Wu J. Poly(disulfide)s: From Synthesis to Drug Delivery. Biomacromolecules 2021. [PMID: 34874705 DOI: 10.1021/acs.biomac.1c01210] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]